The ARL3 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population offering a targeted disruption of the ARL3 gene in the HT29 host background. This product provides a versatile loss-of-function model generated through CRISPR/Cas9-mediated gene disruption, avoiding single-cell clonal selection and thus maintaining a heterogeneous polyclonal composition. The cell population is designed for researchers requiring a robust system to investigate ARL3-dependent cellular processes without the constraints of monoclonal lineage artifacts. As a polyclonal knockout format, it allows the study of gene function across a mixed genetic background, reflecting population-level responses to target gene ablation.
The parental HT29 cell line is a well-characterized human colorectal adenocarcinoma model established from a female patient. These epithelial cells are widely employed as an intestinal epithelial model and retain key features of adenocarcinoma, including dysregulated proliferative signaling. HT29 cells have the capacity to form primary cilia under defined culture conditions, enabling cilia-focused investigations in a cancer cell context. Their adherent growth and ease of genetic manipulation make them a favorable platform for interrogating both ciliary and tumorigenic pathways.
ARL3 encodes a small GTPase that operates within the ARF-like GTPase cycle to orchestrate ciliary trafficking and photoreceptor maintenance. The protein switches between GTP- and GDP-bound states: its active GTP-bound form is generated by the guanine nucleotide exchange factor (GEF) ARL13B, while inactivation is driven by the GTPase-activating protein (GAP) RP2. In its GTP-bound conformation, ARL3 promotes the release of lipidated cargo proteins from their trafficking carriers UNC119 and PDE6D at the ciliary base. This release mechanism is critical for proper delivery of signaling molecules into the cilium. Key interacting factors include RPGR, which cooperates with ARL3 and RP2, and upstream ciliary stimuli that modulate this cycle. Disruption of ARL3 thus impairs ciliary protein localization and downstream signal transduction, linking it to ciliopathies such as retinitis pigmentosa and Joubert syndrome.
In the HT29 colorectal adenocarcinoma setting, ARL3 knockout provides a unique opportunity to dissect ciliary trafficking mechanisms within a cancer-relevant epithelial context. Although HT29 cells are neoplastic, they retain ciliogenic potential and express core ciliary machinery, allowing direct assessment of ARL3-dependent ciliary assembly and cargo delivery. This model bridges the gap between specialized ciliary biology and colorectal cancer signaling, as emerging evidence implicates ciliary proteins in tumor progression. The polyclonal nature of the knockout population further enhances its utility for studying heterogeneous cellular responses, such as ciliation heterogeneity, and for screening assays where clonal variation would confound interpretation.
Researchers can apply this product to a range of experimental settings spanning ciliopathy modeling, photoreceptor biology, and colorectal cancer signaling investigations. The knockout cells are compatible with standard assays including western blotting to confirm ARL3 ablation, immunofluorescence to examine ciliary localization of downstream effectors (e.g., UNC119, ARL13B), cilia formation assays under serum starvation, GTPase activity measurements, co-immunoprecipitation of ARL3 complexes, RT-qPCR for transcript analysis, and cell proliferation assays to probe cancer phenotypes. Drug testing for retinal degeneration and high-content ciliary screens are also feasible. For further technical specifications or assay recommendations, please contact Ascent Research.
